Mary Cushman1, Ellen S O'Meara2, Susan R Heckbert3, Neil A Zakai4, Wayne Rosamond5, Aaron R Folsom6. 1. University of Vermont, United States. Electronic address: mary.cushman@uvm.edu. 2. Group Health Research Institute, United States. 3. University of Washington, United States. 4. University of Vermont, United States. 5. University of North Carolina, Chapel Hill, United States. 6. University of Minnesota, United States.
Abstract
OBJECTIVE: Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. MATERIALS AND METHODS: In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. RESULTS: Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. CONCLUSIONS: Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.
OBJECTIVE:Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. MATERIALS AND METHODS: In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. RESULTS: Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. CONCLUSIONS: Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.
Authors: Sigrid K Braekkan; Knut H Borch; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen Journal: Am J Epidemiol Date: 2010-04-23 Impact factor: 4.897
Authors: Alice M Arnold; Anne B Newman; Mary Cushman; Jingzhong Ding; Stephen Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2009-04-22 Impact factor: 6.053
Authors: Sverre C Christiansen; Inger Anne Naess; Suzanne C Cannegieter; Jens Hammerstrøm; Frits R Rosendaal; Pieter H Reitsma Journal: PLoS Med Date: 2006-08 Impact factor: 11.069
Authors: N S Roetker; S M Armasu; J S Pankow; P L Lutsey; W Tang; M A Rosenberg; T M Palmer; R F MacLehose; S R Heckbert; M Cushman; M de Andrade; A R Folsom Journal: J Thromb Haemost Date: 2017-06-06 Impact factor: 5.824
Authors: Magnus S Edvardsen; Kristian Hindberg; Ellen-Sofie Hansen; Vânia M Morelli; Thor Ueland; Pål Aukrust; Sigrid K Brækkan; Line H Evensen; John-Bjarne Hansen Journal: Blood Adv Date: 2021-01-12
Authors: Miguel Cainzos-Achirica; Michael D Miedema; John W McEvoy; Mary Cushman; Zeina Dardari; Philip Greenland; Khurram Nasir; Matthew J Budoff; Mouaz H Al-Mallah; Joseph Yeboah; Roger S Blumenthal; Josep Comin-Colet; Michael J Blaha Journal: Int J Cardiol Date: 2018-08-01 Impact factor: 4.164
Authors: Line H Evensen; Aaron R Folsom; James S Pankow; John-Bjarne Hansen; Matthew A Allison; Mary Cushman; Pamela L Lutsey Journal: J Thromb Haemost Date: 2021-05-07 Impact factor: 16.036
Authors: Setor K Kunutsor; Samuel Seidu; Ashley W Blom; Kamlesh Khunti; Jari A Laukkanen Journal: Eur J Epidemiol Date: 2017-07-17 Impact factor: 8.082
Authors: Simone A French; Pamela L Lutsey; Wayne Rosamond; Richard F MacLehose; Mary Cushman; Aaron R Folsom Journal: Int J Obes (Lond) Date: 2020-09-18 Impact factor: 5.095
Authors: Francisco Galeano-Valle; Lucía Ordieres-Ortega; Crhistian Mario Oblitas; Jorge Del-Toro-Cervera; Luis Alvarez-Sala-Walther; Pablo Demelo-Rodríguez Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923